Rationale for combination use of targeted agents in ovarian cancer

Do we have one?

Authors

  • Robert L. Coleman MD,

    Corresponding author
    1. Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, 1155 Herman Pressler Drive, Houston, TX 77030
    Search for more papers by this author
    • Fax: (713) 792-7586

  • Elise C. Kohn MD

    1. Molecular Signaling Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
    Search for more papers by this author

  • See referenced original article on pages 723–32, this issue.

Abstract

Current advances in targeted agents for the treatment of ovarian cancer stand on scores of negative clinical studies in tumor types with similar target expression, promising in vitro and in vivo preclinical data, and acceptable safety profiles in their early clinical development. The expanding menu of effective compounds challenges investigators and treating physicians to develop an appropriate rationale for developing novel regimens.

Ancillary